

Past, Present, and Future of Bacillus Calmette-Guérin Vaccine Use: Pharmacists' Perspectives

Hassan Mohammed Ali Alsaab¹, Saud Rajis Aloqayli², Nawaf Ali Alqhtani³, Naif Saud Aldosari⁴, Abdullellah Mansour Alenazi⁵, Mohammed Ahmed Sahloly⁶, Dana Abdulrahman Al Salem⁷, Abdullah Mohammed Al-Arini⁸, Saleh Ali Alghamdi⁹, Mohammed Hazzaa N Almutairi¹⁰, Maher Hezam Mohammed¹¹, Naifah Muharib Raja Alruwaili¹², Fatima Mohammed Ahmed Al-Yami¹³, Bandar Saad Saeed Bin Khater¹⁴, Eman Mohammad Omar Alshammari¹⁵

1. *Pharmacist, Security Forces Hospital, Riyadh, Saudi Arabia.*
2. *Pharmacist, Security forces hospital, Riyadh, Saudi Arabia*
3. *Pharmacist, Security forces hospital, Riyadh, Saudi Arabia*
4. *Pharmacy Technician, Security forces hospital, Riyadh, Saudi Arabia*
5. *Pharmacy Technician, Security forces hospital, Riyadh, Saudi Arabia*
6. *Pharmacist, Prince Sultan Military Medical City, Riyadh, Saudi Arabia*
7. *Pharmacy Specialization, King Saud Hospital in Unaizah, Qassim, Saudi Arabia*
8. *Pharmacist Technician, Compliance Management Branch of The Ministry of Health in Riyadh, Saudi Arabia*
9. *Pharmacist, Compliance management Branch of The Ministry of Health in Riyadh, Saudi Arabia*
10. *Technician - Pharmacy, Prince nassar bin saad alsudary hospital, AlGhat, Saudi Arabia*
11. *Pharmacy Technician, Al Safiah Health Care Center, ALMadinah, Saudi Arabia*
12. *Pharmacy, Prince Miteb bin Abdulaziz Hospital, Al-Jouf (Sakaka), Saudi Arabia*
13. *General Pharmacy, Western Al-Arija Health Center, Riyadh, Saudi Arabia*
14. *Pharmacy Technician, Riyadh, Riyadh District, Saudi Arabia*
15. *Pharmacist, AlYamamah Hospital, Riyadh Second Health Cluster*

Abstract

The Bacillus Calmette-Guérin (BCG) vaccine, developed in the early 20th century by Albert Calmette and Camille Guérin, has a rich history marked by its pivotal role in combating tuberculosis (TB) and its evolving applications in modern medicine. Initially introduced as a preventive measure against TB, the BCG vaccine has demonstrated significant efficacy in reducing severe forms of the disease, particularly in high-risk populations. Over the decades, its use has expanded to include immunotherapy for nonmuscle invasive bladder cancer, showcasing its versatility and the potential for repurposing vaccines in innovative therapeutic contexts. Pharmacists play a crucial role in the distribution, administration, and education surrounding the BCG vaccine. Their expertise in medication management and patient counseling positions them as key stakeholders in vaccination programs. Pharmacists are responsible for ensuring proper vaccine storage, handling, and administration, while also providing essential information to patients regarding the vaccine's benefits, potential side effects, and the importance of adherence to vaccination schedules. Their involvement is vital in addressing vaccine hesitancy and fostering public trust in vaccination efforts. Looking to the future, ongoing

Hassan Mohammed Ali Alsaab¹, Saud Rajis Alogayli², Nawaf Ali Alqhtani³, Naif Saud Aldosari⁴, Abdullellah Mansour Alenazi⁵, Mohammed Ahmed Sahloly⁶, Dana Abdulrahman Al Salem⁷, Abdullah Mohammed Al-Arini⁸, Saleh Ali Alghamdi⁹, Mohammed Hazzaa N Almutairi¹⁰, Maher Hezam Mohammed¹¹, Naifah Muharib Raja Alruwaili¹², Fatima Mohammed Ahmed Al-Yami¹³, Bandar Saad Saeed Bin Khater¹⁴, Eman Mohammad Omar Alshammari¹⁵

research into the BCG vaccine's applications continues to reveal new therapeutic possibilities, including its potential use in treating autoimmune diseases and enhancing immune responses against various infections. As the landscape of vaccine research evolves, pharmacists must remain informed and adaptable, ready to embrace new applications and challenges. Their role as educators and advocates will be increasingly important in navigating the complexities of vaccine science and public health initiatives. This review article explores the historical context, current applications, and future directions of the BCG vaccine, emphasizing the multifaceted contributions of pharmacists in this ongoing narrative. By highlighting their essential role in vaccination efforts, this article aims to underscore the importance of pharmacists in promoting public health and improving patient outcomes through effective vaccine utilization.

Introduction

The Bacillus Calmette-Guérin (BCG) vaccine has a storied history that spans over a century, originating from the early 20th century efforts to combat tuberculosis (TB). Developed by Albert Calmette and Camille Guérin, the vaccine has evolved in its applications and significance, particularly in the realm of public health. The BCG vaccine was the first vaccine developed for the prevention of tuberculosis, a disease that has plagued humanity for centuries, causing immense suffering and loss of life. The historical context of its development is rooted in a time when tuberculosis was one of the leading causes of death worldwide, prompting urgent calls for effective preventive measures. Pharmacists, as integral members of the healthcare team, have played a crucial role in the distribution, administration, and education surrounding the BCG vaccine. Their expertise in medication management, patient counseling, and public health initiatives positions them uniquely to contribute to the success of vaccination programs. This article delves into the historical context of the BCG vaccine, its current applications, and the future directions of its use, all through the lens of pharmacists' perspectives.

The BCG vaccine's journey is not merely a tale of scientific innovation; it is also a narrative of public health response, societal challenges, and the evolving role of healthcare professionals. The development of the BCG vaccine was a response to a pressing public health crisis, and its implementation has required the collaboration of various healthcare stakeholders, including pharmacists. As we explore the past, present, and future of the BCG vaccine, it is essential to recognize the multifaceted contributions of pharmacists in this ongoing story. Their involvement extends beyond mere administration; they are educators, advocates, and key players in the broader public health landscape.

The significance of the BCG vaccine extends beyond its immediate role in tuberculosis prevention. It has also been utilized in the treatment of certain cancers, particularly nonmuscle invasive bladder cancer, showcasing its versatility and the potential for repurposing vaccines in innovative ways. This dual application underscores the importance of ongoing research and the need for healthcare professionals, including pharmacists, to stay informed about the latest developments in vaccine science.

Moreover, the BCG vaccine's historical journey reflects broader societal changes, including shifts in public perception of vaccination, the impact of global health initiatives, and the challenges posed by vaccine hesitancy. Pharmacists are uniquely positioned to address these challenges, serving as trusted sources of information and advocates for vaccination

within their communities. Their role in educating patients about the benefits and risks of vaccination is critical in fostering public trust and ensuring high vaccination rates.

As we look to the future, the potential applications of the BCG vaccine continue to expand, with ongoing research exploring its use in various therapeutic contexts, including autoimmune diseases and infectious diseases beyond tuberculosis. Pharmacists will play a vital role in this evolving landscape, ensuring that patients receive accurate information and appropriate care as new indications for the BCG vaccine emerge.

In summary, the BCG vaccine represents a significant achievement in public health, and its journey is intertwined with the evolving role of pharmacists in healthcare. Their contributions are vital not only in the administration of the vaccine but also in fostering public trust and understanding of vaccination. As we delve deeper into the historical context, current applications, and future directions of the BCG vaccine, we will highlight the essential role that pharmacists play in this ongoing narrative, emphasizing their importance as educators, advocates, and key players in the broader public health landscape.

Historical Context of BCG Vaccine Development

The journey of the BCG vaccine began in the 1900s when tuberculosis was a leading cause of morbidity and mortality worldwide. The initial research aimed to find a way to attenuate the virulence of *Mycobacterium bovis*, the causative agent of bovine tuberculosis. Through a series of subcultures, Calmette and Guérin successfully developed a strain that could stimulate an immune response without causing disease in humans. The first human vaccinations took place in 1921, primarily targeting infants in France.

The early years of the BCG vaccine were marked by optimism and hope. The scientific community recognized the potential of the vaccine to combat a disease that had claimed countless lives. However, despite its promising beginnings, the BCG vaccine faced significant challenges. The Lübeck disaster in 1928, where a contaminated batch of the vaccine led to severe adverse outcomes in infants, cast a long shadow over its acceptance. This incident raised questions about vaccine safety and efficacy, leading to increased scrutiny and hesitance among healthcare providers and the public.

As the understanding of TB and the need for effective preventive measures grew, the BCG vaccine began to gain traction. By the mid-20th century, mass vaccination campaigns were implemented in various countries, leading to a notable decline in TB incidence. Countries such as Sweden, the United Kingdom, and Australia adopted widespread BCG vaccination programs, contributing to significant reductions in TB morbidity and mortality. The historical context of the BCG vaccine is essential for understanding its current applications and the pharmacists' role in its administration. The vaccine's development was not merely a scientific achievement; it was a response to a public health crisis that required collaboration among healthcare professionals, including pharmacists. The lessons learned from the early challenges of the BCG vaccine continue to inform current practices and policies surrounding vaccination.

Current Applications of BCG Vaccine

The BCG vaccine is primarily known for its role in preventing tuberculosis. However, its applications have expanded over the years, particularly in the treatment of certain cancers. Pharmacists are at the forefront of these developments, ensuring that patients receive the vaccine safely and effectively.

Hassan Mohammed Ali Alsaab¹, Saud Rajis Aloqayli², Nawaf Ali Alqhtani³, Naif Saud Aldosari⁴, Abdullellah Mansour Alenazi⁵, Mohammed Ahmed Sahloly⁶, Dana Abdulrahman Al Salem⁷, Abdullah Mohammed Al-Arini⁸, Saleh Ali Alghamdi⁹, Mohammed Hazzaa N Almutairi¹⁰, Maher Hezam Mohammed¹¹, Naifah Muharib Raja Alruwaili¹², Fatima Mohammed Ahmed Al-Yami¹³, Bandar Saad Saeed Bin Khater¹⁴, Eman Mohammad Omar Alshammari¹⁵

Tuberculosis Prevention

The primary indication for the BCG vaccine remains the prevention of tuberculosis, especially in high-risk populations. The vaccine is particularly effective in preventing severe forms of TB, such as disseminated TB and TB meningitis in children. Pharmacists play a vital role in the vaccination process, from educating patients about the importance of vaccination to monitoring for adverse effects.

The efficacy of the BCG vaccine varies significantly across different populations and geographic regions. Studies have shown that the protective effect can range from 0% to 80%, influenced by factors such as genetic diversity, environmental conditions, and the specific strains of the vaccine used. Pharmacists must be aware of these variations to provide accurate information to patients and healthcare providers.

The administration of the BCG vaccine is typically done intradermally, and pharmacists are responsible for ensuring that the vaccine is stored and handled correctly. They also educate patients about the proper care of the injection site to minimize complications, such as local reactions or infections. This educational role is critical, as patients may have concerns about the vaccine's safety and efficacy, particularly in light of historical events like the Lübeck disaster.

Treatment of Bladder Cancer

In addition to its preventive role in tuberculosis, the BCG vaccine has gained recognition as an effective treatment for non-muscle invasive bladder cancer. This application emerged in the 1970s and has since become a standard treatment option. Pharmacists are involved in the preparation and administration of the vaccine for this purpose, ensuring that patients understand the treatment regimen and potential side effects.

The mechanism of action for BCG in bladder cancer involves stimulating the immune system to attack cancer cells. This immunotherapeutic approach has shown promising results, leading to improved outcomes for patients with bladder cancer. Pharmacists play a crucial role in patient management, monitoring for adverse reactions, and providing guidance on managing side effects, which can include urinary symptoms and systemic reactions. The dual role of the BCG vaccine in preventing tuberculosis and treating bladder cancer highlights its versatility and the importance of pharmacists in both contexts. Their expertise in medication management and patient education is essential for optimizing treatment outcomes.

Pharmacists also contribute to the multidisciplinary approach required in cancer care. They collaborate with oncologists, urologists, and nursing staff to ensure that patients receive comprehensive care tailored to their individual needs. This collaboration is vital, as bladder cancer treatment often involves a series of BCG instillations, and pharmacists must ensure that patients adhere to their treatment schedules and understand the importance of followup appointments.

Pharmacists' Role in BCG Vaccine Distribution

Pharmacists are integral to the distribution and administration of the BCG vaccine. Their responsibilities encompass a wide range of activities that ensure the vaccine is delivered safely and effectively to patients. The role of pharmacists extends beyond the pharmacy counter; they are key players in the healthcare system, particularly in vaccination efforts.

One of the primary roles of pharmacists is education and counseling. They provide critical information to patients regarding the importance of vaccination, potential side effects, and the need for follow-up care. This educational aspect is particularly important in the context of the BCG vaccine, as patients may have concerns about its efficacy and safety. Pharmacists must be well-versed in the latest research and guidelines to address these concerns effectively. They often serve as the first point of contact for patients seeking information about the vaccine, making their role in public health education indispensable. Supply chain management is another crucial responsibility for pharmacists. Ensuring a consistent supply of the BCG vaccine is vital, especially given the historical context of shortages due to production issues. Pharmacists must stay informed about the availability of the vaccine and communicate with healthcare providers to manage patient needs effectively. This involves coordinating with manufacturers, understanding inventory levels, and anticipating demand based on vaccination campaigns and patient populations. The ability to navigate these logistical challenges is essential for maintaining vaccination rates and ensuring that high-risk populations receive timely immunization.

Monitoring and reporting are also key components of pharmacists' roles in BCG vaccine distribution. They are often involved in tracking vaccine administration and reporting any adverse events to health authorities. This contributes to the overall safety and efficacy of vaccination programs, as it allows for the identification of potential issues and the implementation of corrective measures. Pharmacists' vigilance in monitoring vaccine outcomes is crucial for maintaining public trust in vaccination programs.

Future Directions in BCG Vaccine Research

The future of the BCG vaccine is promising, with ongoing research exploring its potential applications beyond tuberculosis and bladder cancer. Pharmacists must remain informed about these developments to provide accurate information to patients and healthcare providers. The evolving landscape of vaccine research presents both opportunities and challenges for pharmacists as they adapt to new findings and integrate them into practice.

New Applications and Research

One area of interest is the potential use of the BCG vaccine in treating autoimmune diseases. Preliminary studies suggest that BCG vaccination may have beneficial effects in conditions such as type 1 diabetes and multiple sclerosis. This emerging research could open new avenues for treatment, and pharmacists may play a role in educating patients about these possibilities and managing their treatment plans. As the understanding of the immune system continues to evolve, the potential for BCG to serve as a therapeutic agent in various conditions may expand, necessitating pharmacists' involvement in these innovative treatment strategies.

Another area of exploration is the potential protective effects of the BCG vaccine against COVID-19. While research is ongoing, some studies have suggested that BCG vaccination may enhance the immune response to SARS-CoV-2. Pharmacists must stay updated on the latest findings and be prepared to discuss the implications of this research with patients and healthcare providers. The COVID-19 pandemic has underscored the importance of vaccines in public health, and the BCG vaccine's potential role in this context could lead to renewed interest and research funding.

Hassan Mohammed Ali Alsaab¹, Saud Rajis Aloqayli², Nawaf Ali Alqhtani³, Naif Saud Aldosari⁴, Abdullellah Mansour Alenazi⁵, Mohammed Ahmed Sahloly⁶, Dana Abdulrahman Al Salem⁷, Abdullah Mohammed Al-Arini⁸, Saleh Ali Alghamdi⁹, Mohammed Hazzaa N Almutairi¹⁰, Maher Hezam Mohammed¹¹, Naifah Muharib Raja Alruwaili¹², Fatima Mohammed Ahmed Al-Yami¹³, Bandar Saad Saeed Bin Khater¹⁴, Eman Mohammad Omar Alshammari¹⁵

Enhancing Pharmacists' Role

As the landscape of vaccine research evolves, the role of pharmacists in the administration and education surrounding the BCG vaccine will continue to expand. Pharmacists can enhance their contributions by engaging in continuous professional development, staying informed about the latest research, and participating in public health initiatives. This commitment to lifelong learning is essential for pharmacists to remain effective advocates for vaccination and to provide the best possible care to their patients.

Collaboration with other healthcare professionals is also essential. By working closely with physicians, nurses, and public health officials, pharmacists can ensure that patients receive comprehensive care and that vaccination efforts are coordinated effectively. Interprofessional collaboration fosters a holistic approach to patient care, allowing for the integration of diverse perspectives and expertise in managing vaccination programs.

Conclusion

The Bacillus Calmette-Guérin vaccine has a rich history and continues to play a vital role in public health. From its origins in tuberculosis prevention to its current applications in bladder cancer treatment, the BCG vaccine exemplifies the importance of vaccination in combating infectious diseases and improving patient outcomes. Pharmacists are integral to this process, providing education, managing supply chains, and monitoring patient safety. As research into the BCG vaccine continues to evolve, pharmacists must remain vigilant and adaptable, ready to embrace new applications and challenges. Their expertise will be crucial in navigating the future of vaccine use, ensuring that patients receive the best possible care and that public health initiatives are successful. The journey of the BCG vaccine is far from over, and pharmacists will undoubtedly play a key role in shaping its future.

The ongoing commitment of pharmacists to public health, combined with their unique position within the healthcare system, allows them to advocate for vaccination and educate communities about the benefits and safety of the BCG vaccine. As new research emerges and the landscape of healthcare continues to change, pharmacists will be essential in translating scientific findings into practical applications for patient care.

References:

1. Mangtani et al. "Protection by BCG Vaccine Against Tuberculosis: A Systematic Review of Randomized Controlled Trials" *Clinical infectious diseases* (2013) doi:10.1093/cid/cit790
2. Arbeláez et al. "BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection" *International journal of epidemiology* (2000) doi:10.1093/ije/29.6.1085
3. Abalos et al. "Vaccination of Calves with the Mycobacterium bovis BCG Strain Induces Protection against Bovine Tuberculosis in Dairy Herds under a Natural Transmission Setting" *Animals* (2022) doi:10.3390/ani12091083
4. Gweon et al. "Development of a New Approach to Determine the Potency of Bacille Calmette–Guérin Vaccines Using Flow Cytometry" *Osong public health and research perspectives* (2017) doi:10.24171/j.phrp.2017.8.6.06

5. Moreno-Mendieta et al. "Adjuvants in tuberculosis vaccine development" *Fems immunology & medical microbiology* (2010) doi:10.1111/j.1574-695x.2009.00629.x
6. Jensen et al. "Heterologous Immunological Effects of Early BCG Vaccination in Low-Birth-Weight Infants in Guinea-Bissau: A Randomized-controlled Trial" *The journal of infectious diseases* (2014) doi:10.1093/infdis/jiu508
7. Theilmann et al. "Does early childhood BCG vaccination improve survival into adulthood in a population with a low tuberculosis prevalence? Quasi-experimental evidence on non-specific effects from 39 Swedish birth cohorts" (2023) doi:10.1101/2023.02.16.23286013
8. Hope et al. "Vaccination of neonatal calves with *Mycobacterium bovis* BCG induces protection against intranasal challenge with virulent *M. bovis*" *Clinical & experimental immunology* (2004) doi:10.1111/j.1365-2249.2005.02668.x
9. Covián et al. "BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design" *Frontiers in immunology* (2019) doi:10.3389/fimmu.2019.02806
10. Palmer et al. "Persistence of *Mycobacterium bovis* Bacillus Calmette-Guérin in White-Tailed Deer (*Odocoileus Virginianus*) after Oral or Parenteral Vaccination" *Zoonoses and public health* (2010) doi:10.1111/j.18632378.2010.01329.x
11. Woodworth et al. "A novel *Mycobacterium tuberculosis*-specific subunit vaccine provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin" (2021) doi:10.1101/2021.03.18.435784
12. Cirovic et al. "BCG Vaccination in Humans Elicits Trained Immunity via the Hematopoietic Progenitor Compartment" *Cell host & microbe* (2020) doi:10.1016/j.chom.2020.05.014
13. Miller et al. "Correlation between universal BCG vaccination policy and reduced mortality for COVID-19" (2020) doi:10.1101/2020.03.24.20042937
14. Koster et al. "COVID-19 and Beyond: Exploring Public Health Benefits from Non-Specific Effects of BCG Vaccination" *Microorganisms* (2021) doi:10.3390/microorganisms9102120
15. Dockrell and Smith "What Have We Learnt about BCG Vaccination in the Last 20 Years?" *Frontiers in immunology* (2017) doi:10.3389/fimmu.2017.01134
16. Sumner "Modelling the health and economic impacts of M72/AS01_E vaccination and BCG-revaccination: estimates for South Africa" (2023) doi:10.1101/2023.10.04.23296538
17. Goodridge et al. "Harnessing the beneficial heterologous effects of vaccination" *Nature reviews immunology* (2016) doi:10.1038/nri.2016.43
18. Tran et al. "Loss of Lipid Virulence Factors Reduces the Efficacy of the BCG Vaccine" *Scientific reports* (2016) doi:10.1038/srep29076
19. Roth et al. "BCG vaccination scar associated with better childhood survival in Guinea-Bissau" *International journal of epidemiology* (2005) doi:10.1093/ije/dyh392
20. Klinger et al. "Significantly Improved COVID-19 Outcomes in Countries with Higher BCG Vaccination Coverage: A Multivariable Analysis" (2020) doi:10.20944/preprints202006.0073.v1

Hassan Mohammed Ali Alsaab¹, Saud Rajis Aloqayli², Nawaf Ali Alqhtani³, Naif Saud Aldosari⁴, Abdullellah Mansour Alenazi⁵, Mohammed Ahmed Sahloly⁶, Dana Abdulrahman Al Salem⁷, Abdullah Mohammed Al-Arini⁸, Saleh Ali Alghamdi⁹, Mohammed Hazzaa N Almutairi¹⁰, Maher Hezam Mohammed¹¹, Naifah Muharib Raja Alruwaili¹², Fatima Mohammed Ahmed Al-Yami¹³, Bandar Saad Saeed Bin Khater¹⁴, Eman Mohammad Omar Alshammari¹⁵

21. Birk et al. "Effects of Bacillus Calmette-Guérin (BCG) vaccination at birth on T and B lymphocyte subsets: Results from a clinical randomized trial" *Scientific reports* (2017) doi:10.1038/s41598-017-11601-6
22. Padmapriyadarsini et al. "Revisiting the Chingleput BCG vaccination trial for the impact of BCG revaccination on the incidence of tuberculosis disease" *The indian journal of medical research* (2023) doi:10.4103/ijmr.ijmr_1540_22
23. Giamarellos-Bourboulis et al. "Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly" *Cell* (2020) doi:10.1016/j.cell.2020.08.051
24. Clark et al. "New tuberculosis vaccines in India: modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01E and BCGrevaccination" *Bmc medicine* (2023) doi:10.1186/s12916-023-02992-7
25. Clark et al. "New tuberculosis vaccines in India: Modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01_E and BCG-revaccination" (2023) doi:10.1101/2023.02.24.23286406